<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269827</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1A-I-007</org_study_id>
    <secondary_id>other grant</secondary_id>
    <nct_id>NCT01269827</nct_id>
  </id_info>
  <brief_title>Pentoxifylline and Systemic Inflammation in Hemodialysis Patients</brief_title>
  <official_title>Randomized, Double-Blinded, Controlled Clinical Trial of the Effect Pentoxifylline vs Placebo on the Serum Concentrations of TNF-a, IL-6 and CRP of Patients in Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the effect of PTX vs placebo on serum concentrations of&#xD;
      TNF-α, IL-6, and CRP in patients on hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomly selected from the total HD patients of our hospital. Once included,&#xD;
      patients were randomly allocated (by a computer-generated randomization list) to a study or&#xD;
      control group. Over a period of 4 months, patients of the study group received one PTX tablet&#xD;
      (400 mg) orally once a day (at dinner time), whereas controls received one starch identical&#xD;
      tablet on the same schedule.&#xD;
&#xD;
      All patients had three HD sessions per week, with the same kind of single-use dialysis&#xD;
      membrane and dialysate. Monthly visits were scheduled for clinical and biochemical&#xD;
      evaluations. A blood sample was taken at baseline and every month for measurement of complete&#xD;
      blood count, urea, creatinine, glucose, albumin, lipids, and electrolytes (measured by usual&#xD;
      methods). In serum samples at 0, 2 and 4 months, TNF-α and IL-6 concentrations were measured&#xD;
      by ELISA using high sensitivity kits (Amersham Pharmacia Biotech, Buckinghamshire, UK).&#xD;
      Additionally, in the same serum samples, CRP concentrations were measured by nephelometry&#xD;
      using high sensitivity kits (Dade Behring, Marburg, Germany) in a Nephelometry Analyzer II&#xD;
      (Dade Behring, Marburg, Germany). All laboratory measurements, including inflammation&#xD;
      markers, were performed in the Central Laboratory (Hospital de Especialidades, CMNO), by the&#xD;
      same personnel blinded to patient's details.&#xD;
&#xD;
      Treatment compliance was recorded by counting tablets left in the container at the end of&#xD;
      each monthly visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum levels of TNF-a, IL-6 and CRP</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Inflammation</condition>
  <condition>End-stage Renal Disease</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)</description>
    <arm_group_label>pentoxifylline</arm_group_label>
    <other_name>trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>starch tablets</intervention_name>
    <description>Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years,&#xD;
&#xD;
          -  ≥2 months on HD,&#xD;
&#xD;
          -  arteriovenous fistula as vascular access, and&#xD;
&#xD;
          -  endorsement of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inflammatory cause of ESRD,&#xD;
&#xD;
          -  liver disease, cancer, AIDS,&#xD;
&#xD;
          -  any infectious disease 2 months before the study,&#xD;
&#xD;
          -  failed kidney graft,&#xD;
&#xD;
          -  hypersensitivity to PTX or other methylxanthines,&#xD;
&#xD;
          -  hemorrhage/clotting disorders,&#xD;
&#xD;
          -  risk for worsening pre-existing cardiac arrhythmias or arterial hypotension,&#xD;
&#xD;
          -  treatment with antibiotics, non-steroidal anti-inflammatory drugs, steroids,&#xD;
             immunosuppressives, statins or PTX 3 months previous to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso M. M Cueto-Manzano, MD, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad de Investigación Médica en Enfermedades Renales, Hospital de Especialidades, CMNO, IMSS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Especialidades, CMNO, IMSS</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Alfonso Martín Cueto Manzano</investigator_full_name>
    <investigator_title>Jefe de Unidad de Investigación Médica en Enfermedades Renales, HE, CMNO, IMSS</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>pentoxifylline</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

